Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 28 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Orchid Pharma Ltd

About the Company - Orchid Pharma Ltd

Orchid Pharma Ltd. is a Public Limited Listed company incorporated on 01/07/1992 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24222TN1992PLC022994 and registration number is 022994. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 556.97 Cr. and Equity Capital is Rs. 40.82 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals'Orchid Towers', 313, Valluvar Kottam High Road, Chennai (Madras) Tamil Nadu 600034corporate@orchidpharma.com
http://www.orchidpharma.com
Management
NamePosition Held
Mr. Ram Gopal AgarwalChairman & Non-Exe.Director
Mr. Manish DhanukaManaging Director
Mr. Mridul DhanukaWhole Time Director
Mrs. Tanu SinglaIndependent Director
Dr. Dharam VirIndependent Director
Mr. Manoj Kumar GoyalIndependent Director
Mr. Mudit TandonIndependent Director

Orchid Pharma Ltd. Share Price Update

Share PriceValue
Today₹1,015.85
Previous Day₹878.70

Basic Stock Data of Orchid Pharma Ltd

Market Cap 6,122 Cr.
Current Price 1,207
High / Low1,360/362
Stock P/E71.8
Book Value 218
Dividend Yield0.00 %
ROCE4.97 %
ROE0.95 %
Face Value 10.0

Data Source: screener.in

Competitors of Orchid Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Brooks Laboratories Ltd 319 Cr. 122186/56.5 30.10.00 %27.7 %23.4 % 10.0
TTK Healthcare Ltd 2,096 Cr. 1,4841,584/82832.2 6880.69 %10.1 %99.7 % 10.0
Aarey Drugs & Pharmaceuticals Ltd 122 Cr. 48.068.0/21.928.9 46.80.00 %6.38 %3.33 % 10.0
Nectar Lifescience Ltd 874 Cr. 39.045.7/14.4108 47.60.00 %0.18 %6.01 % 1.00
Vaishali Pharma Ltd 168 Cr. 159204/11528.8 41.80.00 %21.7 %19.7 % 10.0
Industry Average715.80 Cr370.4039.58170.860.14%13.21%30.43%8.20

Orchid Pharma Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales10910312092128161178131165160210183199
Expenses9110812395116147152119147146170161175
Operating Profit18-5-4-3111426121814402223
OPM %17%-5%-3%-3%9%9%14%10%11%9%19%12%12%
Other Income1211368-1-03693428
Interest131312111074898764
Depreciation3029202020202722188788
Profit before tax-24-45-25-3149-14-5-14-37591120
Tax %0%0%0%0%0%0%0%0%0%0%0%0%0%
Net Profit-24-45-25-3149-14-7-15-5859920
EPS in Rs-5.98-10.96-6.06-7.5712.10-3.40-1.61-3.68-1.321.8614.491.853.90

Orchid Pharma Ltd Quarterly Chart

Orchid Pharma Ltd Profit & Loss

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,7821,8741,9481,747873797683600484450560666751
Expenses1,4371,5171,8371,429703794659612515421505581653
Operating Profit345357110317171324-12-3129558499
OPM %19%19%6%18%20%0%4%-2%-6%7%10%13%13%
Other Income775292156-28-59202182415675253
Interest1171805235372943473107652333325
Depreciation134154252325145141133130118109875531
Profit before tax17275-573-389-296-544-39969-131-11724897
Tax %9%-29%2%49%6%9%12%0%0%0%0%0%
Net Profit15697-560-197-279-495-35369-131-117-24696
EPS in Rs22.1713.84-79.21-23.06-31.37-55.69-39.657.80-32.11-28.55-0.4811.3522.10
Dividend Payout %14%22%0%0%0%0%0%0%0%0%0%0%

Orchid Pharma Ltd Profit & Loss Yearly Chart

Orchid Pharma Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:-1%
3 Years:11%
TTM:28%
Compounded Profit Growth
10 Years:%
5 Years:15%
3 Years:27%
TTM:588%
Stock Price CAGR
10 Years:38%
5 Years:218%
3 Years:18%
1 Year:160%
Return on Equity
10 Years:%
5 Years:%
3 Years:-6%
Last Year:1%

Orchid Pharma Ltd Balance Sheet

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital70707085898989894141414151
Reserves9991,062310244-40-556-881-7937256126076481,057
Borrowings2,0792,0053,2043,2113,2153,1063,2023,230566453268331147
Other Liabilities7628011,067521598616715551128132195205237
Total Liabilities3,9103,9384,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,492
Fixed Assets1,7422,0742,5841,7951,6371,4971,3861,256858670584573564
CWIP332352360282280288272278267104663
Investments11111110015454447
Other Assets1,8351,5111,7061,9841,9441,4701,4671,542576544472561818
Total Assets3,9103,9384,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,492

Orchid Pharma Ltd Reserves and Borrowings Chart

Orchid Pharma Ltd Cash Flow

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 332737168-36921240191281249218
Cash from Investing Activity -367-293-9861,334-1-176-284516767113-31
Cash from Financing Activity -78-480664-597-286-46533-0-250-165-21731
Net Cash Flow-113-36-153367-76-2401557-2-74-1118

Orchid Pharma Ltd Financial Efficiency Indicators

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days10522345413075647351110111118
Inventory Days259279187118220196202214254244201217
Days Payable141186220146341402374381182176195173
Cash Conversion Cycle224114-0269-130-108-94123179117163
Working Capital Days-3634-1138697-226-505-735166305136154
ROCE %10%8%-3%1%1%-4%-4%-5%-6%-5%-2%5%

Orchid Pharma Ltd Financial Efficiency Indicators Chart

Orchid Pharma Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters98.07%90.00%90.00%90.00%90.00%89.96%89.96%89.96%89.96%72.40%72.40%69.84%
FIIs0.04%1.82%1.79%1.78%1.61%1.48%1.37%0.86%0.81%8.58%8.08%4.14%
DIIs1.00%3.67%3.35%3.35%2.97%2.97%2.98%3.94%2.62%13.48%12.46%14.51%
Government0.00%0.00%0.04%0.04%0.04%0.04%0.00%0.00%0.00%0.00%0.00%0.00%
Public0.89%4.51%4.83%4.84%5.39%5.55%5.69%5.22%6.60%5.54%7.05%11.52%
No. of Shareholders30,34333,37934,79833,53333,69833,67932,71730,89429,52329,13229,19736,931

Orchid Pharma Ltd Shareholding Pattern Chart

No. of Orchid Pharma Ltd Shareholders

Orchid Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Quant Small Cap Fund15349190.7887.28
Quant Multi Asset Fund12625966.2371.8
Nippon India Pharma Fund10000000.9256.87
Quant Value Fund6684324.2938.01
UTI Small Cap Fund4450000.7325.3
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund2696670.4715.33
Tata Multi Asset Opportunities Fund1752600.489.97
Tata India Pharma & HealthCare Fund1750001.329.95
UTI Healthcare Fund1000000.675.69

Orchid Pharma Ltd ROCE Trend

Orchid Pharma Ltd EPS Trend

Orchid Pharma Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)11.35-0.48-28.55-14.757.80
Diluted EPS (Rs.)11.35-0.48-28.55-14.757.80
Cash EPS (Rs.)25.3021.71-1.87-1.2622.41
Book Value[Excl.RevalReserv]/Share (Rs.)168.72158.61159.96250.97-79.14
Book Value[Incl.RevalReserv]/Share (Rs.)168.72158.61159.96250.97-79.14
Revenue From Operations / Share (Rs.)163.14137.09110.26124.4767.44
PBDIT / Share (Rs.)25.2515.2215.93-0.24-0.14
PBIT / Share (Rs.)11.82-6.10-10.76-31.09-14.75
PBT / Share (Rs.)13.54-13.94-23.34-32.117.80
Net Profit / Share (Rs.)11.880.38-28.55-32.117.80
NP After MI And SOA / Share (Rs.)11.35-0.47-28.55-32.117.80
PBDIT Margin (%)15.4711.1014.44-0.19-0.21
PBIT Margin (%)7.24-4.44-9.75-24.98-21.87
PBT Margin (%)8.29-10.16-21.16-25.7911.56
Net Profit Margin (%)7.270.28-25.89-25.7911.56
NP After MI And SOA Margin (%)6.95-0.34-25.89-25.7911.56
Return on Networth / Equity (%)6.72-0.30-17.84-12.79-9.85
Return on Capital Employeed (%)5.65-2.86-4.00-8.23-17.88
Return On Assets (%)3.78-0.17-9.41-7.612.25
Long Term Debt / Equity (X)0.210.320.650.48-2.02
Total Debt / Equity (X)0.480.410.650.48-3.01
Asset Turnover Ratio (%)0.570.470.300.210.19
Current Ratio (X)1.351.873.873.250.29
Quick Ratio (X)0.731.152.792.390.22
Inventory Turnover Ratio (X)2.022.091.601.441.43
Interest Coverage Ratio (X)3.201.941.27-0.23-4.26
Interest Coverage Ratio (Post Tax) (X)1.50-0.77-0.85-30.52-437.99
Enterprise Value (Cr.)1869.701420.3010472.28346.981842.00
EV / Net Operating Revenue (X)2.812.5423.270.683.07
EV / EBITDA (X)18.1422.86161.10-350.31-1442.21
MarketCap / Net Operating Revenue (X)2.362.0722.360.040.07
Price / BV (X)2.281.7915.410.02-0.06
Price / Net Operating Revenue (X)2.362.0722.360.040.07
EarningsYield0.020.00-0.01-6.121.46

Orchid Pharma Ltd Profitability Ratios (%)

Orchid Pharma Ltd Liquidity Ratios

Orchid Pharma Ltd Liquidity Ratios (%)

Orchid Pharma Ltd Interest Coverage Ratios (%)

Orchid Pharma Ltd Valuation Ratios

Fair Value / Intrinsic Value of Orchid Pharma Ltd

Fair Value: ₹151.67

The stock is overvalued by 87.43% compared to the current price ₹1207

*Investments are subject to market risks

Strength and Weakness of Orchid Pharma Ltd

StrengthWeakness
  1. The stock has a low average Working Capital Days of -53.08, which is a positive sign.
  1. The stock is trading at a high valuation with an average P/B ratio of -10.18 and average Dividend Yield of -10.76%.
  2. The stock has a low average ROCE of -0.33%, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 51.92, which may not be favorable.
  4. The company has higher borrowings (1,924.38) compared to reserves (307.23), which may suggest financial risk.
  5. The company has not shown consistent growth in sales (451.38) and profit (-152.77).

Should I Buy Orchid Pharma Ltd Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Orchid Pharma Ltd:
    1. Net Profit Margin: 7.27%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 5.65% (Industry Average ROCE: 20.1%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 1.50
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 0.73
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✗ Stock P/E: 64.8 (Industry average Stock P/E: 32.7)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.48
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Orchid Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE